GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthaverse SA (WAR:SVE) » Definitions » Cyclically Adjusted Price-to-FCF

Synthaverse (WAR:SVE) Cyclically Adjusted Price-to-FCF : (As of Jun. 01, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Synthaverse Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synthaverse Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Synthaverse's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthaverse Cyclically Adjusted Price-to-FCF Chart

Synthaverse Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synthaverse Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synthaverse's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Synthaverse's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthaverse's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthaverse's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Synthaverse's Cyclically Adjusted Price-to-FCF falls into.


;
;

Synthaverse Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Synthaverse's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Synthaverse's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.03/153.4391*153.4391
=0.030

Current CPI (Sep. 2024) = 153.4391.

Synthaverse Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.031 100.122 0.048
201503 0.007 100.041 0.011
201506 0.005 100.448 0.008
201509 -0.660 99.634 -1.016
201512 -0.365 99.471 -0.563
201603 0.201 98.983 0.312
201606 -0.432 99.552 -0.666
201609 0.024 99.064 0.037
201612 0.426 100.366 0.651
201703 0.069 101.018 0.105
201706 0.032 101.180 0.049
201709 0.063 101.343 0.095
201712 -0.065 102.564 -0.097
201803 -0.070 102.564 -0.105
201806 0.019 103.378 0.028
201809 -0.011 103.378 -0.016
201812 0.008 103.785 0.012
201903 0.055 104.274 0.081
201906 -0.039 105.983 -0.056
201909 0.097 105.983 0.140
201912 0.004 107.123 0.006
202003 0.006 109.076 0.008
202006 -0.068 109.402 -0.095
202009 -0.002 109.320 -0.003
202012 0.037 109.565 0.052
202103 -0.037 112.658 -0.050
202106 -0.013 113.960 -0.018
202109 -0.157 115.588 -0.208
202112 -0.134 119.088 -0.173
202203 -0.001 125.031 -0.001
202206 -0.121 131.705 -0.141
202209 -0.208 135.531 -0.235
202212 -0.191 139.113 -0.211
202303 -0.130 145.950 -0.137
202306 -0.469 147.009 -0.490
202309 -0.599 146.113 -0.629
202312 -0.481 147.741 -0.500
202403 -0.131 149.044 -0.135
202406 -0.237 150.997 -0.241
202409 0.030 153.439 0.030

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synthaverse  (WAR:SVE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Synthaverse Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Synthaverse's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthaverse Business Description

Industry
Traded in Other Exchanges
N/A
Address
10, Uniwersytecka street, Lublin, POL, 20-029
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.

Synthaverse Headlines

No Headlines